Abstract
The ability of proteins to fold to their functional states is an astonishing example of the power of biological evolution at the molecular level. Despite the large number of different native protein folds, the process of folding can be described in terms of a universal mechanism that appears to be based on the generation of the correct overall topology through interactions involving a relatively small number of residues. Protein misfolding is an intrinsic aspect of normal folding within the complex cellular environment, and its effects are minimized in living systems by the action of a range of protective mechanisms including molecular chaperones and quality control systems. Unfolded and misfolded proteins have a tendency to aggregate to form a variety of species including the highly organized and kinetically stable amyloid fibrils. The latter species represent a generic form of structure resulting from the inherent polymer properties of polypeptide chains, and their formation is associated with a wide range of debilitating human diseases. Amyloid fibrils and their precursors appear to have similar adverse effects on cellular function regardless of the sequence of the component peptide or protein. Our increasing knowledge of the interplay between different forms of protein structure and their generic characteristics provides a platform for rational therapeutic intervention designed to prevent or treat this whole family of diseases.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Balbach, J., and Schmid, F.X. (2000). Proline isomerization and its catalysis in protein folding. In: Pain, R.H. (Ed.), Protein folding, 2nd ed. Oxford: Oxford University Press, pp. 212–249.
Ban, T., Hamada, D., Hasegawa, K., Naiki, H., and Goto, Y. (2003). Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem. 278:16462–16465.
Bence, N.F., Sampat, R.M., and Kopito, R.R. (2001). Impairment of the ubiquitin-proteosome system by protein aggregation. Science 292:1552–1555.
Bitan, G., Kirkitadze, M.D., Lomakin, A., Vollers, S.S., Benedek, G.B., and Teplow, D.B. (2003). Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA 100:330–335.
Booth, D.R., Sunde, M., Bellotti, V., Robinson, C.V., Hutchinson, W.L., Fraser, P.E., Hawkins, P.N., Dobson, C.M., Radford, S.E., Blake, C.C.F., and Pepys, M.B. (1997). Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385:787–793.
Bouchard, M., Zurdo, J., Nettleton, E.J., Dobson, C.M., and Robinson, C.V. (2000). Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 9:1960–1967.
Branden, C., and Tooze, J. (1999). Introduction to protein structure. 2nd ed. New York: Garland Publishing.
Broome, B.M., and Hecht, M.H. (2000). Nature disfavours sequences of alternating polar and non-polar amino acids: implications for amyloidogenesis. J. Mol. Biol. 296:961–968.
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C.M., and Stefani, M. (2002). Inherent cytotoxicity of aggregates implies a common origin for protein misfolding diseases. Nature 416:507–511.
Bucciantini, M., Calloni, G., Chiti, F., Formighi, L., Nosi, D., Dobson, C.M., and Stefani, M. (2004). Pre-fibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. 279:31374–31382.
Capaldi, A.P., Kleanthous, C., and Radford, S.E. (2002). Im7 folding mechanism: misfolding on a path to the native state. Nat. Struct. Biol. 9:209–216.
Caughey, B., and Lansbury, P.T., Jr. (2003). Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26:267–298.
Chamberlain, A.K., MacPhee, C.E., Zurdo, J., Morozova-Roche, L.A., Hill, H.A., Dobson, C.M., and Davis, J.J. (2000). Ultrastructural organisation of amyloid fibrils by atomic force microscopy. Biophys. J. 79:3282–3293.
Cheung, M.S., Garcia, A.E., and Onuchic, J.N. (2002). Protein folding mediated by solvation: water expulsion and formation of the hydrophobic core occur after the structural collapse. Proc. Natl. Acad. Sci. USA 99:685–690.
Chien, P., DePace, A.H., Collins, S.R., and Weissman, J.S. (2003). Generation of prion transmission barriers by mutational control of amyloid conformations. Nature 424:948–951.
Chien, P., Weismann, J.S., and DePace, A.H. (2004). Emerging principles of conformation-based prion inheritance. Annu. Rev. Bio Chem. 73:617–656.
Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., and Dobson, C.M. (1999). Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. USA 96:3590–3594.
Chiti, F., Taddei, N., Baroni, F., Capanni, C., Stefani, M., Ramponi, G., and Dobson, C.M. (2002). Kinetic partitioning of protein folding and aggregation. Nat. Struct. Biol. 9:137–143.
Chiti, F., Stefani, M., Taddei, N., Ramponi, G., and Dobson, C.M. (2003). Rationalisation of mutational effects on peptide and protein aggregation rates. Nature 424:805–808.
Cohen, F.E., and Kelly, J.W. (2003). Therapeutic approaches to protein-misfolding diseases. Nature 426:905–909.
Csermely, P. (2001). Chaperone overload is a possible contributor to “civilization diseases.” Trends Gen. 17:701–704.
Davis, R., Dobson, C.M., and Vendruscolo, M. (2002). Determination of the structures of distinct transition state ensembles for a β-sheet peptide with parallel folding pathways. J. Chem. Phys. 117:9510–9517.
Debe, D.A., Carlson, M.J., and Goddard, W.A., III. (1999). The topomer-sampling model of protein folding. Proc. Natl. Acad. Sci. USA 96:2596–2601.
Dill, K.A., and Chan, H.S. (1997). From Levinthal to pathways to funnels. Nat. Struct. Biol. 4:10–19.
Dobson, C.M. (1999). Protein misfolding, evolution and disease. Trends Biochem. Sci. 24:329–332.
Dobson, C.M. (2001). The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. Lond. B 356:133–145.
Dobson, C.M. (2002). Getting out of shape—protein misfolding diseases. Nature 418:729–730.
Dobson, C.M. (2003). Protein folding and misfolding. Nature 426:884–890.
Dobson, C.M. (2004a). In the footsteps of alchemists. Science 295:1719–1722.
Dobson, C.M. (2004b). Principles of protein folding, misfolding and aggregation. Semin. Cell Dev. Biol. 15:3–16.
Dobson, C.M., and Karplus, M. (1999). The fundamentals of protein folding: bringing together theory and experiment. Curr. Opin. Struct. Biol. 9:92–101.
Dobson, C.M., Sali, A., and Karplus, M. (1998). Protein folding: a perspective from theory and experiment. Angew. Chem. Int. Ed. Eng. 37:868–893.
DuBay, K.F., Pawar, A.P., Chiti, F., Zurdo, J., Dobson, C.M., and Vendruscolo, M. (2004). Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. J. Mol. Biol. 341:1317–1326.
Dumoulin, M., and Dobson, C.M. (2005). Probing the origins, diagnosis and treatment of amyloid disease using antibodies. Biochimie. 86:589–600.
Dumoulin, M., Last, A.M., Desmyter, A., Decanniere, K., Canet, D., Spencer, A., Archer, D.B., Muyldermans, S., Wyns, L., Matagne, A., Redfield, C., Robinson, C.V., and Dobson, C.M. (2003). A camelid antibody fragment inhibits amyloid fibril formation by human lysozyme. Nature 424:783–788.
Ellis, R.J. (Ed.). (1996). The chaperonins. San Diego, CA: Academic Press.
Ellis, R.J., and Hartl, F.U. (1999). Principles of protein folding in the cellular environment. Curr. Opin. Struct. Biol. 9:102–110.
Ellis, R.J., and Minton, A.P. (2003). Join the crowd. Nature 425:27–28.
Fändrich, M., and Dobson, C.M. (2002). The behaviour of polyamino acids reveals an inverse side-chain effect in amyloid structure formation. EMBO J. 21:5682–5690.
Fändrich, M., Fletcher, M.A., and Dobson, C.M. (2001). Amyloid fibrils from muscle myoglobin. Nature 410:165–166.
Fersht, A.R. (1999). Structure and mechanism in protein science: a guide to enzyme catalysis and protein folding. New York: W.H. Freeman.
Fersht, A.R. (2000). Transition-state structure as a unifying basis in protein-folding mechanisms: contact order, chain topology, stability, and the extended nucleus mechanism. Proc. Natl. Acad. Sci. USA 97:1525–1529.
Fersht, A.R. and Daggett, V. (2002). Protein folding and unfolding at atomic resolution. Cell 108:573–582.
Gejyo, F., Homma, N., Suzuki, Y., and Arakawa, M. (1986). Serum levels of β2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N. Engl. J. Med. 314:585–586.
Gilbert, R.J.C, Fucini, P., Connell, S., Fuller, S.D., Nierhaus, K.H., Robinson, C.V., Dobson, C.M., and Stuart, D.I. (2004). Three-dimensional structures of translating ribosomes by cryo-EM. Mol. Cell. 14:57–66.
Hammarstrom, P., Wiseman, R.L., Powers, E.T., and Kelly, J.W. (2003). Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299:713–716.
Hardesty, B., and Kramer, G. (2001). Folding of a nascent peptide on the ribosome. Prog. Nucleic Acid Res. Mol. Biol. 66:41–66.
Harper, J.D., and Lansbury, P.T., Jr. (1997). Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Bioi Chem. 66:385–407.
Hartl, F.U., and Hayer-Hartl, M. (2002). Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295:1852–1858.
Höppener, J.W.M., Nieuwenhuis, M.G., Vroom, T.M., Ahrén, B., and Lips, C.J.M. (2002). Role of islet amyloid in type 2 diabetes mellitus: consequence or cause? Mol. Cell. Endocrinol. 197:205–212.
Hore, P.J., Winder, S.L., Roberts, C.H., and Dobson, C.M. (1997). Stopped-flow photo-CIDNP observation of protein folding. J. Am. Chem. Soc. 119:5049–5050.
Horwich, A. (2002). Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J. Clin Invest. 110:1221–1232.
Jackson, S.E. (1998). How do small single-domain proteins fold? Fold. Des. 3:R81–R91.
Jaroniec, C.P., MacPhee, C.E., Bajaj, V.S., McMahon, M.T., Dobson, C.M., and Griffin, R.G. (2004). High resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy. Proc. Natl. Acad. Sci. USA 101:711–716.
Jenni, S., and Ban, N. (2003). The chemistry of protein synthesis and voyage through the ribosomal tunnel. Curr. Opin. Struct. Biol. 13:212–219.
Jiménez, J.L., Guijarro, J.I., Orlova, E., Zurdo, J., Dobson, C.M., Sunde, M. and Saibil, H.R. (1999). Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18:815–821.
Jiménez, J.L., Nettleton, E.J., Bouchard, M., Robinson, C.V., Dobson, C.M., and Saibil, H.R. (2002). The protofilament structure of insulin amyloid fibrils. Proc. Natl. Acad. Sci. USA 99:9196–9201.
Karplus, M. (1997). The Levinthal paradox, yesterday and today. Fold. Des. 2:569–576.
Karplus, M., and Weaver, D.L. (1994). Folding dynamics: the diffusion-collision model and experimental data. Protein Sci. 3:650.
Kaufman, R.J. (2002). The unfolded protein response in nutrient sensing and differentiation. Nat. Rev. Mol. Cell Biol. 3:411–421.
Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., and Glabe, C.G. (2003). Common structure of soluble amyloid oligomers implies common mechanisms of pathogenesis. Science 300:486–489.
Kelly, J. (1998). Alternative conformation of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8:101–106.
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 55:306–319.
Koo, E.H., Lansbury, P.T., Jr., and Kelly, J.W. (1999). Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. USA 96:9989–9990.
Korzhnev, D.M., Salvatella, X., Vendruscolo, M., Di Nardo, A.A., Davidson, A.R., Dobson, C.M., and Kay, L.E. (2004). Low populated folding intermediates of the Fyn SH3 domain characterized by relaxation dispersion NMR. Nature 430:586–590.
Krebs, M.R.H, MacPhee, C.E., Miller, A.F., Dunlop, I.E., Dobson, C.M., and Donald, A.M. (2004). The formation of spherulites by amyloid fibrils of bovine insulin. Proc. Natl. Acad. Sci. USA 101:14420–14424.
Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., Lansbury, P.T., Jr. (2002). Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418:291.
Legname, G., Baskakov, I.V., Nguyen, H.O., Riesner, D., Cohen, F.E., DeArmond, S.J., and Prusiner, S.J. (2004). Synthetic mammalian prions. Science 305:673–676.
Lindorff-Larsen, K., Vendruscolo, M., Paci, E., and Dobson, C.M. (2004). Transition states for protein folding have native topologies despite high structural variability. Nat. Struct. Mol. Biol. 11:443–439.
Lopez de la Paz, M., Goldie, K., Zurdo, J., Lacrois, E., Dobson, C.M., Hoenger, A., and Serrano, L. (2002). De novo designed peptide-based amyloid fibrils. Proc. Natl. Acad. Sci. USA 99:16052–16057.
Macario, A.J.L., and de Macario, E.C. (2002). Sick chaperones and ageing: a perspective. Ageing Res. Rev. 1:295–311.
Makarov, D.E., and Plaxco, K.W. (2003). The topomer search model: a simple, quantitative theory of two-state protein folding kinetics. Protein Sci. 12:17–26.
Malisauskas, M., Zamotin, V., Jass, J., Noppe, W., Dobson, C.M., and Morozova-Roche, L.A. (2003). Amyloid protofilaments from the calcium-binding protein equine lysozyme: formation of ring and linear structures depends on pH and metal ion concentration. J. Mol. Biol. 330:879–890.
Matouschek, A., Kellis, J.T., Jr., Serrano, L., and Fersht, A.R. 1989. Mapping the transition state and pathway of protein folding by protein engineering. Nature 342:122.
May, B.C., Fafarman, A.T., Hong, S.B., Rogers, M., Deady, L.W., Prusiner, S.B., and Cohen, F.E. (2003). Potent inhibition of scrapie prion replication in cultured cells by bisacridines. Proc. Natl. Acad. Sci. USA 100:3416–3421.
Miller, M.W., and Williams, E.S. (2003). Horizontal prion transmission in male deer. Nature 425:35–36.
Muchowski, P.J., Schaffar, G., Sittler, A., Wanker, E.E., Hayer-Hartl, M.K., and Hartl, F.U. (2000). Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. USA 97:7841–7846.
Nettleton, E.J., Tito, P., Sunde, M., Bouchard, M., Dobson, C.M., and Robinson, C.V. (2000). Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. Biophys. J. 79:1053–1065.
O’Nuallain, B., and Wetzel, B. (2002). Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. USA 99:1485–1490.
Paci, E., Friel, C., Lindorff-Larsen, K., Radford, S., Karplus, M., and Vendruscolo, M. (2004). Comparison of the transition states ensembles for folding of Im7 and Im9 determined using all-atom molecular dynamics simulations with Ф value restraints. Proteins 54:513–525.
Padrick, S.B., and Miranker, A.D. (2002). Islet amyloid phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. Biochemistry 41:4694–4703.
Panchenko, A.R., Luthey-Schulter, Z., and Wolynes, P.G. (1996). Foldons, protein structureal modules, and exons. Proc. Natl. Acad. Sci. USA 93:2008–2013.
Pelham, H.R. 1986. Speculations on the functions of the major heat shock and glucose-regulated proteins. Cell 46:959–961.
Pepys, M.B. (1995). Amyloidosis. In: Weatherall, D.J., Ledingham, J.G.G., and Warrell, D.A. (Eds.). The Oxford textbook of medicine, 3rd ed. Oxford: Oxford University Press, pp.1512–1524.
Pepys, M.B., et al. (2002). Targeted pharmocological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254–259.
Petkova, A.T., Ishii, Y., Balbach, J.J., Antzutkin, O.N., Leapman, R.D., Delaglio, F., and Tycko, R. (2002). A structural model for Alzheimer’s β-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. USA 99:16742–16747.
Plakoutsi, G., Taddei, N., Stefani, M., and Chiti, F. (2004). Aggregation of the acylphosphatase from sulfolobus solfataricus: the folded and partially unfolded states can both be precursors for amyloid formation. J. Biol. Chem. 279:14111–14119.
Polverino de Laureto, P., Taddei, N., Frare, E., Capanni, C., Constantini, S., Zurdo, J., Chiti, F., Dobson, C.M., and Fontana, A. (2003). Protein aggregatin and amyloid fibril formation by an SH3 domain probed by limited proteolysis. J. Mol. Biol. 334:129–141.
Prusiner, S. (1997). Prion diseases and the BSE crisis. Science 278:245–251.
Ramirez-Alvarado, M., Merkel, J.S., and Regan, L. (2000). A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc. Natl. Acad. Sci. USA 97:8979–8984.
Richardson, J.S., and Richardson, D.C. (2002). Natural β-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc. Natl. Acad. Sci. USA 99:2754–2759.
Rousseau, F., Schymkowitz, J.W., Wilkinson, H.R., and Itzhaki, L.S. (2004). Intermediates control domain swapping during folding of p13suc1. J. Biol. Chem. 279:8368–8377.
Schenck, D. (2002). Amyloid-β immunotherapy for Alzheimer’s disease: the end of the beginning. Nat. Rev. Neurosci. 3:824–828.
Schiene, C., and Fisher, G. (2000). Enzymes that catalyse the restructuring of proteins. Curr. Opin. Struct. Biol. 10:40.
Schlunegger, M.P., Bennett, M.J., and Eisenberg, D. (1997). Oligomer formation by 3D domain swapping: a model for protein assembly and misassembly. Adv. Protein Chem. 50:61–122.
Schubert, U., Anton, L.C., Gibbs, J., Orbyry, C.C., Yewdell, J.W., and Bennink, J.R. (2000). Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404:770–774.
Selkoe, D.J. (2003). Folding proteins in fatal ways. Nature 426:900–904.
Serpell, L.C, Blake, C.C.F., and Fraser, P.E. (2000). Molecular structure of a fibrillar Alzheimer’s Aß fragment. Biochemistry 39:13269–13275.
Sherman, M.Y., and Goldberg, A.L. (2001). Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29:15–32.
Shorter, J., and Lindquist, S. (2004). Hsp104 catalyzes formation and elimination of self-replicating Sup35 pion conformers. Science 304:1793–1797.
Sitia, R., and Braakman, I. (2003). Quality control in the endoplasmic reticulum folding factory. Nature 426:891–894.
Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4:49–60.
Stangou, A.J., Hawkins, P.N., Booth, D.R., O’Grady, J., Jewitt, D., Rela, M., Pepys, M.B., and Heaton, N.D. (1999). Liver transplantation for non-Met30 TTR associated familial amyloid polyneuropathy. Hepatology 30:576.
Stefani, M., and Dobson, C.M. (2003). Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81:678–699.
Sunde, M., and Blake, C.C. (1997). F, the structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv. Protein Chem. 50:123–159.
Tan, S.Y., and Pepys, M.B. (1994). Amyloidosis. Histophathology 25:403–414.
Thomas, P.J., Qu, B.H., and Pedersen, P.L. (1995). Defective protein folding as a basis of human disease. Trends Bio Chem. Sci. 20:456–459.
Trieber, D.K., and Williamson, J.R. (1999). Exploring the kinetic traps in RNA folding, Curr. Opin. Struct. Biol. 9:339–345.
Uversky, V.N., and Fink, A.L. (2004). Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 1698:131–153.
Vendruscolo, M., and Dobson, C.M. (2005). Towards complete descriptions of the free energy landscapes of proteins. Philos. Trans. R. Soc. Lond A. 363:433–452.
Vendruscolo, M., Paci, E., Dobson, C.M., and Karplus, M. (2001). Three key residues form a critical contact network in a transition state for protein folding. Nature 409:641–646.
Vendruscolo, M., Zurdo, J., MacPhee, C.E., and Dobson, C.M. (2003). Protein folding and misfolding: a paradigm of self-assembly and regulation in complex biological systems. Philos. Trans. R. Soc. Lond. A 361:1205–1222.
Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., and Selkoe, D.J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539.
Wille, H., Michelitsch, M.D., Guenebaut, V., Supattapone, S., Serban, A., Cohen, F.E., Agard, D.A., and Prusiner, S.B. (1999). Structural studies of the scrapie prion protein by electron crystallography. Proc. Natl. Acad. Sci. USA 99:3563–3568.
Wilson, M.R., and Easterbrook-Smith, S.B. (2000). Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 25:95–98.
Wolfe, M.S. (2002). Secretase as a target for Alzheimer’s disease. Curr. Top. Med. Chem. 2:371–383.
Wolynes, P.G., Onuchic, J.N., and Thirumalai, D. (1995). Navigating the folding routes. Science 267:1619–1623.
Woolhead, C.A., McCormick, P.J., and Johnson, A.E. (2004). Nascent membrane and secretory proteins differ in FRET-detected folding far inside the ribosome and in their exposure to ribosomal proteins. Cell 116:725–736.
Yusupov, M.M., Yusupova, G.Z., Baucom, A., Lieberman, K., Earnest, T.N., Cate, J.H., and Noller, H.F. (2001). Crystal structure of the ribosome at 5.5 Å resolution. Science 292:883–896.
Zurdo, J., Guijarro, J.I., Jiménez, J.L., Saibil, H.R., and Dobson, C.M. (2001). Dependence on solution conditions of aggregation and amyloid formation by an SH3 domain. J. Mol. Biol. 311:325–340.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Dobson, C.M. (2006). The Generic Nature of Protein Folding and Misfolding. In: Uversky, V.N., Fink, A.L. (eds) Protein Misfolding, Aggregation, and Conformational Diseases. Protein Reviews, vol 4. Springer, Boston, MA. https://doi.org/10.1007/0-387-25919-8_2
Download citation
DOI: https://doi.org/10.1007/0-387-25919-8_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25918-5
Online ISBN: 978-0-387-25919-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)